WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H540063
CAS#: 70356-03-5 (hydrate)
Description: Cefaclor monohydrate is a penicillin binding protein inhibitor that prevents peptidoglycan synthesis and bacterial cell wall formation. It also enhances phagocytosis, bacterial activity of granulocytes and macrophages, and slows gastric emptying and intestinal transit.
Hodoodo Cat#: H540063
Name: Cefaclor monohydrate
CAS#: 70356-03-5 (hydrate)
Chemical Formula: C15H16ClN3O5S
Exact Mass: 385.05
Molecular Weight: 385.810
Elemental Analysis: C, 46.70; H, 4.18; Cl, 9.19; N, 10.89; O, 20.73; S, 8.31
Related CAS #: 70356-03-5 (hydrate) 53994-73-3 (free)
Synonym: Ceclor; Keclor; S6472; S-6472; S 6472; LS-149967; LS149967; LS 149967;
IUPAC/Chemical Name: (6R,7R)-7-((R)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
InChi Key: WKJGTOYAEQDNIA-IOOZKYRYSA-N
InChi Code: InChI=1S/C15H14ClN3O4S.H2O/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7;/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23);1H2/t9-,10-,14-;/m1./s1
SMILES Code: O=C(C(N12)=C(Cl)CS[C@]2([H])[C@H](NC([C@H](N)C3=CC=CC=C3)=O)C1=O)O.[H]O[H]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 385.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Medenecka B, Jelińska A, Zajac M, Bałdyka M, Juszkiewicz K, Oszczapowicz I. Stability of the crystalline form of cefaclor monohydrate and its pharmaceutical preparations. Acta Pol Pharm. 2009 Sep-Oct;66(5):563-9. PubMed PMID: 19894653.
2: Olsen BA, Perry FM, Snorek SV, Lewellen PL. Accelerated conditions for stability assessment of bulk and formulated cefaclor monohydrate. Pharm Dev Technol. 1997 Nov;2(4):303-12. PubMed PMID: 9552459.
3: Aggarwal M, Sinha R, Murali MV, Trihan P, Singhal PK. Comparative efficacy and safety evaluation of cefaclor vs amoxycillin + clavulanate in children with Acute Otitis Media (AOM). Indian J Pediatr. 2005 Mar;72(3):233-8. PubMed PMID: 15812119.
4: Scardina GA, Conti NM, Messina P. [Cefaclor induced pemphigus vulgaris]. Minerva Stomatol. 2004 Jan-Feb;53(1-2):61-6. Italian. PubMed PMID: 15041921.
5: Aggarwal M, Sinha R, Murali MV, Trihan P, Singhal PK. Comparative efficacy and safety evaluation of cefaclor VS amoxycillin + calvulanate in children with Acute Otitis Media (AOM). Indian J Pediatr. 2005 Mar;72(3):233-238. doi: 10.1007/BF02859264. PubMed PMID: 28378172.
6: Umut S, Tutluoglu B, Aydin Tosun G, Müsellim B, Erk M, Yildirim N, Vahapoglu H, Yilmaz N, Arseven O, Türker H, Erelel M, Ilvan A, Göylüsün V, Yilmaz Kuyucu T, Koşar F, Soysal F, Gür A, Unutmaz S, Oztürk S, Akman M. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group. J Chemother. 1999 Jun;11(3):211-4. PubMed PMID: 10435684.
7: Yoo HS, Kim SH, Kwon HS, Kim TB, Nam YH, Ye YM, Park HS. Immunologic evaluation of immediate hypersensitivity to cefaclor. Yonsei Med J. 2014 Nov;55(6):1473-83. doi: 10.3349/ymj.2014.55.6.1473. PubMed PMID: 25323882; PubMed Central PMCID: PMC4205685.
8: Thomas PW, Cammarata M, Brodbelt JS, Fast W. Covalent inhibition of New Delhi metallo-β-lactamase-1 (NDM-1) by cefaclor. Chembiochem. 2014 Nov 24;15(17):2541-8. doi: 10.1002/cbic.201402268. Epub 2014 Oct 10. PubMed PMID: 25302694.
9: Huang C, Wang W, Miao L. Determination of cefaclor by UPLC-MS-MS for a Chinese pharmacokinetic study. J Chromatogr Sci. 2014 Aug;52(7):636-40. doi: 10.1093/chromsci/bmt092. Epub 2013 Jul 9. PubMed PMID: 23839802.
10: Zhang Z, Xiang Y, Wang B, Chen H, Cai X, Wang X, Mei L, Zheng Y. Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions. Eur J Pediatr. 2013 Apr;172(4):537-43. doi: 10.1007/s00431-012-1926-y. Epub 2013 Jan 8. PubMed PMID: 23296953.
11: Rasool BK, Fahmy SA. Development of coated beads for oral controlled delivery of cefaclor: In vitro evaluation. Acta Pharm. 2013 Mar;63(1):31-44. doi: 10.2478/acph-2013-0003. PubMed PMID: 23482311.
12: Tomić Z, Tomas A, Vukmirović S, Mikov M, Horvat O, Tomić N, Sabo A. Do We Bury Antibacterials When Launching? Cefaclor Example. J Pharm Sci. 2016 Mar;105(3):1295-300. doi: 10.1016/j.xphs.2015.12.003. Epub 2016 Jan 30. PubMed PMID: 26886327.
13: van de Streek J, Rantanen J, Bond AD. Structures of cefradine dihydrate and cefaclor dihydrate from DFT-D calculations. Acta Crystallogr C. 2013 Nov;69(Pt 11):1229-33. doi: 10.1107/S0108270113026863. Epub 2013 Oct 19. PubMed PMID: 24192164.
14: Bottaro G, Biasci P, Lo Giudice M, Mele G, Montanari G, Napoleone E, Santucci A, Tucci PL, Fano M, Biraghi MG. [5 days Cefaclor vs. 10 days amoxicillin/clavulanate in the treatment of childhood streptococcal pharyngitis. Data from a randomized clinical trial]. Minerva Pediatr. 2012 Jun;64(3):341-6. Italian. PubMed PMID: 22555328.
15: Tarawneh KA, Halasah ZA, Khleifat AM, Batarseh MI, Khleifat KM, Al-Mustafa AH. Evaluation of cefaclor oral suspensions stability using reversed phase high performance liquid chromatography and antimicrobial diffusion methods. Pak J Pharm Sci. 2011 Jul;24(3):303-13. PubMed PMID: 21715263.
16: Chen J, Jiang B, Lou H, Yu L, Ruan Z. Bioequivalence studies of 2 oral cefaclor capsule formulations in chinese healthy subjects. Arzneimittelforschung. 2012 Mar;62(3):134-7. doi: 10.1055/s-0031-1298012. Epub 2012 Jan 27. PubMed PMID: 22286978.
17: Qian JQ, Correra TC, Li J, Maître P, Song DQ, Hu CQ. Differentiation of cefaclor and its delta-3 isomer by electrospray mass spectrometry, infrared multiple photon dissociation spectroscopy and theoretical calculations. J Mass Spectrom. 2015 Jan;50(1):265-9. doi: 10.1002/jms.3510. PubMed PMID: 25601701.
18: Abbatangelo R, Mascelloni R, Cavani E, Prete C. [Use of cefaclor monohydrate in infections of the upper and lower respiratory tract]. Clin Ter. 1988 Aug 31;126(4):261-5. Italian. PubMed PMID: 2974395.
19: Ma J, Bellon M, Wishart JM, Young RL, Jones KL, Horowitz M, Rayner CK. Effects of cefaclor on gastric emptying and cholecystokinin release in healthy humans. Regul Pept. 2010 Jan 8;159(1-3):156-9. doi: 10.1016/j.regpep.2009.11.009. PubMed PMID: 19914303.
20: Vetter F, Pohl J, Pohl B, Bracher F. Analysis of cefaclor in novel chocolate-based camouflage capsules. Pharmazie. 2014 Jun;69(6):455-7. PubMed PMID: 24974581.
